Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 5/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741270 | 0.84 | HTR1A (0.57) | HTR7HTR1ADRD2TMEM97SIGMAR1 | |
| SCHEMBL4946260 | 0.84 | TMEM97 (0.57) | SLC2A1HTR1AKCNH2TMEM97SIGMAR1 | |
| SCHEMBL4685443 | 0.83 | HTR1A (0.58) | HTR7HTR1ADRD2TMEM97SIGMAR1 | |
| SCHEMBL4684256 | 0.81 | HTR1A (0.58) | SLC2A1HTR7HTR1ADRD2TMEM97 | |
| SCHEMBL5848982 | 0.77 | KCNH2 (0.75) | HTR7HTR1ADRD2KCNH2SIGMAR1 | |
| SCHEMBL1706541 | 0.76 | KCNH2 (0.79) | HTR7HTR1ADRD2KCNH2SIGMAR1 | |
| SCHEMBL8267105 | 0.76 | HTR1A (0.43) | SLC2A1HTR7HTR1ADRD2TMEM97 | |
| SCHEMBL5009487 | 0.73 | HTR7 (0.52) | HTR7HTR1ADRD2KCNH2DRD4 | |
| SCHEMBL7566159 | 0.73 | HRH3 (0.58) | HTR7HTR1ADRD2DRD4HTR2A | |
| SCHEMBL4687501 | 0.72 | SIGMAR1 (0.67) | HTR7HTR1ADRD2SIGMAR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | BIOPROJET (FR) | 2008-09-04 | — | — | US | disclosed |
| EP-1828125-B1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET SOC CIV (FR) | 2008-04-09 | — | — | EP | disclosed |
| EP-1828125-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANGS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006058993-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANDS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214542-A1 | Arylpiperazine Derivatives and their Use as Selective Dopamine D3 Receptor Ligands | SLC6A3, ADRB3, PRLHR | SLC2A1 2299/4885HTR7 39/4885HTR1A 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.